North America Sarcopenia Treatment Market
No. of Pages: 72 | Report Code: BMIRE00030523 | Category: Life Sciences
No. of Pages: 72 | Report Code: BMIRE00030523 | Category: Life Sciences
The North America sarcopenia treatment market was valued at US$ 1,451.12 million in 2022 and is expected to reach US$ 2,273.85 million by 2030; it is estimated to register a CAGR of 5.8% from 2022 to 2030. Upsurge in Geriatric Population Fuels North America Sarcopenia Treatment Market
The geriatric population is prone to sarcopenia, orthopedic disorders, metabolic disorders, and neurological disorders, among others. Sarcopenia is a geriatric illness characterized by a progressive loss of the mass and strength of skeletal muscles. It is associated with a higher risk of unfavorable health outcomes, e.g., falls, disabilities, institutionalization, poor quality of life, and mortality. The elderly populace is rising rapidly in developed countries. According to the World Health Organization (WHO), the aging population across the world is likely to rise from ~1 billion in 2019 to ~2.1 billion by 2050. Also, according to the 2020 Census, the population of US 65 and older increased about five times faster than the total population during the 100 years between 1920 and 2020. In 2020, the number of older populations reached 55.8 million, or 16.8% of the total population of the US.
Aging results in a reduction in muscle mass as one of the major changes in body composition. A significant decline in food consumption among elderly people is one of the key factors causing the loss of muscle mass. According to the National Library of Medicine, people from the age group of 50-60 lose nearly 1.5% of muscle strength every year, while 1-2% of muscle mass is lost annually after the age of 60. Compared to general populations, elderly patients had a higher prevalence of sarcopenia. According to an article published in June 2023 in Elsevier, the prevalence of sarcopenia ranges from 18% in diabetic patients to 66% in those with incurable esophageal cancer. Hence, the rising elderly population contributes significantly to the sarcopenia treatment market growth.North America Sarcopenia Treatment Market Overview
The sarcopenia treatment market in North America is segmented into the US, Canada, and Mexico. North America accounted for the largest share of the global market in 2022. The sarcopenia treatment market growth in North America is attributed to the rising adoption of nutraceutical supplements for the treatment. In addition, the surging prevalence of orthopedic disorders with the increasing number of cases of vitamin B12 and vitamin D deficiency in the geriatric population fuels the market in this region.
Sarcopenia prevalence varies with age and gender; elderly people residing in assisted living facilities or communities in the US are at a higher risk of developing this condition. According to the National Institute of Health, in 2019, the anticipated hospitalization cost for persons with sarcopenia in the US was US$ 40.4 billion. People with sarcopenia pay US$ 2,315 more for hospital visits than people with normal muscle mass and function every year on average; they are almost twice as likely to be hospitalized than people without sarcopenia. Additionally, a 10% decrease in the loss of skeletal muscle can prevent the possible comorbidity of sarcopenia and save around US$ 1 billion in annual US medical care expenses.
Strategic insights for the North America Sarcopenia Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the North America Sarcopenia Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.North America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)
Get more information on this report North America Sarcopenia Treatment Strategic Insights
Get more information on this report North America Sarcopenia Treatment Report Scope
Report Attribute
Details
Market size in 2022
US$ 1,451.12 Million
Market Size by 2030
US$ 2,273.85 Million
Global CAGR (2022 - 2030)
5.8%
Historical Data
2020-2021
Forecast period
2023-2030
Segments Covered
By Treatment Type
By Distribution Channel
Regions and Countries Covered
North America
Market leaders and key company profiles
Get more information on this report North America Sarcopenia Treatment Regional Insights
Get more information on this report
North America Sarcopenia Treatment Market Segmentation
The North America sarcopenia treatment market is categorized into treatment type, distribution channel, and country.
Based on treatment type, the North America sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest North America sarcopenia treatment market share in 2022.
In terms of distribution channel, the North America sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest North America sarcopenia treatment market share in 2022.
By country, the North America sarcopenia treatment market is segmented into the US, Canada, and Mexico. The US dominated the North America sarcopenia treatment market share in 2022.
Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, GSK Plc, and Makers Nutrition LLC are some of the leading companies operating in the North America sarcopenia treatment market.
1. Abbott Laboratories
2. Bayer AG
3. Metagenics LLC
4. Nestle Health Science SA
5. Novartis AG
6. Pfizer Inc
7. Sanofi SA
8. Amway Corp
9. GSK Plc
10. Makers Nutrition LLC
The North America Sarcopenia Treatment Market is valued at US$ 1,451.12 Million in 2022, it is projected to reach US$ 2,273.85 Million by 2030.
As per our report North America Sarcopenia Treatment Market, the market size is valued at US$ 1,451.12 Million in 2022, projecting it to reach US$ 2,273.85 Million by 2030. This translates to a CAGR of approximately 5.8% during the forecast period.
The North America Sarcopenia Treatment Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Sarcopenia Treatment Market report:
The North America Sarcopenia Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Sarcopenia Treatment Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Sarcopenia Treatment Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Sarcopenia Treatment Market
